HIV and PrEP: Prevention, Testing, and Modern Treatment
Sarah, a 34-year-old marketing manager, sat in my office convinced that if she contracted HIV, she’d have AIDS within a few years and face a severely shortened lifespan. She wasn’t alone in this belief. Here’s what’s actually true: someone diagnosed with HIV today who starts antiretroviral therapy promptly has a near-normal life expectancy—studies show life expectancy of 55+ additional years for those starting treatment in their 30s. The virus no longer equals a death sentence. But there’s a misconception worth correcting right away: HIV and AIDS are not the same thing. HIV is the virus; AIDS is what happens when your CD4+ count drops below 200 cells per microliter or you develop certain opportunistic infections. With modern treatment, many people with HIV never progress to AIDS at all.
Key Facts About HIV
- Approximately 1.2 million people live with HIV in the United States, with roughly 36,500 new infections annually according to CDC data
- Undetectable equals untransmittable (U=U): people with HIV whose viral load is below 50 copies/mL cannot transmit the virus sexually, even without condoms
- PrEP (pre-exposure prophylaxis) reduces HIV transmission risk by 99% when taken consistently for sexual exposure, and 74% when taken as directed for injection drug use
- The median CD4+ count in healthy people is 500-1,500 cells per microliter; below 200 indicates AIDS
- Current first-line antiretroviral combinations suppress HIV to undetectable levels in 90%+ of patients within 6 months of consistent adherence
Understanding HIV: How the Virus Actually Works
HIV is a retrovirus—it reverse-engineers your own cells’ machinery. Think of it like a burglar who doesn’t steal from a house but instead rewires the house to manufacture counterfeit currency. The virus enters your CD4+ T cells (the white blood cells that coordinate your immune response) by binding to a receptor called CCR5 or CXCR4. Once inside, it releases an enzyme called reverse transcriptase that converts its RNA genome into DNA, which then integrates into your cell’s DNA. Your cell becomes a factory producing new HIV particles. The virus doesn’t kill you directly through the infection itself; the problem emerges over months or years as HIV destroys more and more CD4+ cells, gradually weakening your immune system’s ability to fight off other infections and certain cancers.
What many people don’t understand is that HIV hides. Your immune system can attack the virus, but HIV mutates rapidly—it’s one of the fastest-mutating organisms we know. That’s why a single antiretroviral drug fails within weeks: the virus simply evolves resistance. Modern treatment uses combinations of drugs from different classes, making it nearly impossible for the virus to develop resistance to all of them simultaneously. It’s like changing three different locks on a door at once rather than one.
Causes and Risk Factors
HIV transmits through four main routes: sexual contact (anal intercourse carries the highest per-act transmission risk at roughly 1.4%, vaginal intercourse at 0.08%, receptive oral sex at 0.04%), blood exposure (needle sharing among people who inject drugs, occupational needlestick injuries in healthcare workers), mother-to-child transmission during pregnancy or breastfeeding, and occasionally through transfusion of untested blood products.
The virus cannot spread through saliva, sweat, tears, or casual contact. You cannot get HIV from sharing food, bathrooms, or hugging someone with HIV. Mosquitoes don’t transmit it. Yet here’s the clinical insight most health websites skip: viral load dramatically affects transmission risk. Someone with an undetectable viral load (below 50 copies/mL) poses essentially zero sexual transmission risk. This means treatment itself becomes prevention—a concept called treatment as prevention (TasP) that fundamentally changed public health strategy.
One less-discussed risk factor involves sexually transmitted infections. Having another STI like gonorrhea or chlamydia increases your HIV acquisition risk by 2-5 fold because these infections cause inflammation and increase CD4+ cell density at mucosal surfaces—essentially creating a larger target for HIV. Untreated sexually transmitted infections matter clinically.
Signs and Symptoms: What Patients Actually Experience
Some people experience acute retroviral syndrome 2-4 weeks after exposure—fever, sore throat, fatigue, muscle aches, and sometimes a rash. It feels like severe flu. Others notice nothing. Many unknowingly carry the virus for months or years because they have no symptoms. This asymptomatic period lasts differently for different people: some progress slowly over 10+ years; others progress in 3-5 years without treatment.
As the CD4+ count drops lower, patients report progressive exhaustion, recurrent oral thrush (a yeast infection in the mouth), persistent diarrhea, unexplained weight loss, and swollen lymph nodes. These aren’t specific to HIV, which is why testing matters. When CD4+ counts fall below 200, opportunistic infections emerge—Pneumocystis pneumonia (PCP), cytomegalovirus (CMV) infections, and toxoplasma encephalitis become real risks. The key overlooked warning sign: oral thrush. Most patients dismiss it as a minor annoyance, but recurrent oral thrush in someone with undiagnosed HIV should trigger testing.
Diagnosis: Testing and What to Expect
Diagnosis starts with screening. The standard fourth-generation antigen/antibody test detects both HIV antibodies and the p24 antigen (part of the virus itself), which means it catches infections within 18-45 days of exposure—the diagnostic window. A negative result from 45+ days after potential exposure is reliable. If screening is positive, the next step is confirmatory testing using HIV-1/HIV-2 differentiation immunoassay or an HIV-1 nucleic acid test (RNA test). The RNA test is more sensitive in early infection.
Once diagnosed, you’ll need baseline labs: CD4+ count, viral load (HIV RNA), and resistance testing (genotyping) to identify which drugs your specific virus is susceptible to. You should also be tested for hepatitis B and C, syphilis, and tuberculosis. Then comes the conversation about starting antiretroviral therapy. Most guidelines recommend starting immediately—the benefits of early suppression outweigh waiting. The process from diagnosis to first dose of medication typically takes 1-3 weeks in well-resourced settings.
Treatment Options: Modern Antiretroviral Therapy
First-line treatment typically combines three drugs from at least two different classes. A common regimen might be tenofovir/emtricitabine (Truvada or generic) plus dolutegravir (Tivicay). Dolutegravir is an integrase strand transfer inhibitor—it blocks the enzyme that integrates viral DNA into your genome. The tenofovir/emtricitabine combination blocks reverse transcriptase in two different ways. Together, they achieve undetectable viral loads in over 90% of patients within 6 months.
For some patients, long-acting options exist. Cabotegravir and rilpivirine can be given as monthly or bi-monthly injections rather than daily pills, which improves adherence for people struggling with medication regimens. Other first-line options include darunavir/cobicistat (a protease inhibitor approach) or efavirenz-based regimens, though efavirenz carries more neuropsychiatric side effects and is less commonly used now.
What matters most is adherence. Taking 95%+ of doses is necessary to prevent resistance. Missing doses sporadically doesn’t mean failure—one missed dose out of 30 is generally fine. But skipping several consecutive days allows resistant virus to emerge. Most patients tolerate modern regimens well, with side effects like nausea or diarrhea being manageable and often resolving within weeks.
Practical Daily Management
Take your antiretroviral medications on schedule every day. Set phone reminders if needed. Link medication-taking to an existing habit—brush teeth, then take HIV meds. Don’t skip doses to avoid side effects; call your provider instead to discuss alternatives. Get your CD4+ count and viral load checked every 3 months initially, then every 6-12 months once suppressed. Maintain regular appointments with an HIV specialist (an infectious disease physician or HIV medicine specialist). Self-managing alone often leads to gaps in care.
Tell sexual partners your status before exposure. If you’re undetectable, you can disclose that U=U applies and transmission risk is zero. If you’re not yet suppressed, use condoms. For partners without HIV, discuss PrEP with their provider if appropriate. Maintain routine vaccinations—you’ll need pneumococcal vaccine, annual flu shot, and possibly other vaccines depending on your CD4+ count. Get screened for cervical or anal cancer depending on your sex assigned at birth and sexual practices. These cancers occur at higher rates in people with HIV, especially if CD4+ counts remain below 200.
Prevention: PrEP and Other Strategies
Pre-exposure prophylaxis (PrEP) is antiretroviral medication taken by HIV-negative people to prevent infection. The two FDA-approved daily pill options are tenofovir/emtricitabine (Truvada) and tenofovir alafenamide/emtricitabine (Descovy). Descovy is preferred for people assigned female at birth because it achieves better levels in female genital tissues. There’s also cabotegravir/rilpivirine as a monthly or bi-monthly injection alternative. PrEP effectiveness depends entirely on consistent use: 99% effective for sexual transmission with daily adherence, but drops to 76% if taken inconsistently.
PrEP works best for people at substantial risk: anyone in a serodiscordant relationship (one partner with HIV, one without), men who have sex with men with multiple partners, people who inject drugs and share equipment, or anyone in a high-prevalence network. You need baseline kidney function testing and HIV testing before starting (you must be truly negative). On PrEP, you need HIV and kidney function testing every 3-6 months. Some people experience side effects like nausea or mild bone density changes, but serious complications are rare.
Other prevention strategies include condoms (85-95% effective in real-world use), limiting number of sexual partners, and post-exposure prophylaxis (PEP)—taking antiretroviral medications within 72 hours of potential exposure to prevent infection. The evidence from NIH and CDC studies shows combining methods works better: someone using both condoms and PrEP reduces their HIV risk to nearly zero.
Frequently Asked Questions About HIV
Related Health Articles
Sources & Medical References
HealthTopics.com articles are based on peer-reviewed medical research and guidance from the NIH, CDC, and WHO. See our editorial policy for full sourcing standards.
